Clinical breast cancer最新文献

{"title":"Comparison of Systemic Inflammatory Indices With the Oncotype DX Recurrence Score and the Nottingam Prognostic Index in Early Hormone Receptor Positive Ductal Breast Cancer.","authors":"Anita M Huws, Gareth R Davies, Paul D Lewis, Claire Morgan","doi":"10.1016/j.clbc.2024.11.022","DOIUrl":"https://doi.org/10.1016/j.clbc.2024.11.022","url":null,"abstract":"<p><strong>Background: </strong>Adjuvant therapy decisions in hormone receptor positive, HER2 negative breast cancer are evolving. Gene panel testing has reduced the number of patients recommended for chemotherapy by up to two thirds. Identifying low risk genomic cases before testing could represent a significant economic impact. Systemic inflammatory indices have shown promise as prognostic markers in early breast cancer. We investigated the utility of four systemic inflammatory indices with the Nottingham Prognostic Index to predict the Oncotype DX® recurrence scores threshold level (low or high score), in women aged 50 and over with node negative invasive ductal carcinoma of the breast.</p><p><strong>Methods: </strong>A retrospective review of 245 patients with Oncotype DX® Recurrence Score testing from 2007 to 2021 were identified. The Nottingham Prognostic Index and systemic inflammatory indices ratios were estimated from histology results and preoperative peripheral blood samples respectively.</p><p><strong>Results: </strong>22.4% of the cohort had a Recurrence Score in the higher risk group. This group had a greater percentage of grade 3 tumours, progesterone receptor negativity, higher Nottingham Prognostic Scores, and inflammatory indices ratios than the lower risk group. A decision tree incorporating the Neutrophil Lymphocyte Ratio with clinicopathological features showed potential as an indicator of a high Oncotype DX® RS score, such that further investigation is warranted to assess whether Recurrence Score testing could be triaged in certain cohorts of patients. In this study, 38% of patients might be able to avoid genomic testing based on the decision tree analysis.</p><p><strong>Conclusion: </strong>Utility of inflammatory indices with clinicopathological features may help triage gene panel testing.</p>","PeriodicalId":10197,"journal":{"name":"Clinical breast cancer","volume":" ","pages":""},"PeriodicalIF":2.9,"publicationDate":"2024-12-07","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142902629","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Development and Evaluation of a Remote Monitoring Regional Adjuvant Abemaciclib Service for Patients With High-Risk Early Breast Cancer.","authors":"Nicole L Brown, Ann Tivey, Suzanne Frank, Siow Chin Phua, Jack E Johnson, Anne Armstrong, Caroline Wilson, Sophie Raby, Sophie Low, Yvonne Hulmes, Fiona Britton, Sacha J Howell","doi":"10.1016/j.clbc.2024.12.001","DOIUrl":"https://doi.org/10.1016/j.clbc.2024.12.001","url":null,"abstract":"<p><strong>Introduction: </strong>Adjuvant abemaciclib was recently approved in high-risk early breast cancer, leading to an increase in oncology resource utilisation. We thus developed a regional, remote monitoring clinical service. The set-up, delivery processes and outcomes from the first 6 months' consecutive patients are presented.</p><p><strong>Methods: </strong>A regional delivery model with remote monitoring using optional electronic patient outcome measures (ePROMs) and bloods closer to home (BCTH) was implemented. Electronic patient records of patients entering the service (October 31, 2022 to May 31, 2023) were reviewed. Time-in-motion and on-line patient satisfaction surveys were conducted with questions adapted from prior questionnaires used by our cancer center. An independent t-test was used to assess differences in creatinine levels whilst on abemaciclib and a Mann-Whitney test to determine whether the time taken to complete follow-up appointments differed with and without ePROMs.</p><p><strong>Results: </strong>The first 103 patients to commence abemaciclib (median age 58 [range, 27-85], 66.0% White) had completed a median of 6 cycles (range, 0-9). 51.5% had treatment interruption, 52.4% a dose reduction and 15.5% discontinued therapy. Diarrhoea (90.3%), fatigue (84.9%) and anorexia (73.1%) were the most commonly reported toxicities on ePROMs. 10.8% of patients reported grade 3-4 toxicities. Neutropenia was also common and low grade. 89.5% of patients would recommend ePROMs and 98.0% found the BCTH service easy to use. Review appointments with ePROMs were a similar length to those without (P = .138).</p><p><strong>Conclusions: </strong>We have successfully implemented a remote, regional adjuvant clinical service which could serve as a blueprint for other NHS trusts for this and other cancer drugs.</p>","PeriodicalId":10197,"journal":{"name":"Clinical breast cancer","volume":" ","pages":""},"PeriodicalIF":2.9,"publicationDate":"2024-12-07","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142945688","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Axillary Reverse Mapping Using Indocyanine Green in Breast Cancer: Standardization of the Technique","authors":"Ortega-Expósito Carlos ,&nbsp;Pla Maria ,&nbsp;Campos Miriam ,&nbsp;Falo Catalina ,&nbsp;Perez-Montero Hector ,&nbsp;Azcarate Juan ,&nbsp;Benítez Ana ,&nbsp;Salinas Sira ,&nbsp;Bosch Jan ,&nbsp;Aranguena-Peñacoba Marina ,&nbsp;Pernas Sonia ,&nbsp;Ponce Jordi ,&nbsp;Garcia-Tejedor Amparo","doi":"10.1016/j.clbc.2024.12.003","DOIUrl":"10.1016/j.clbc.2024.12.003","url":null,"abstract":"<div><h3>Purpose</h3><div>To validate the Axillary Reverse Mapping (ARM) technique with indocyanine green (ICG), focusing on the detection rate and the procedure's feasibility. The predictive factors for metastatic involvement of ARM nodes are also analyzed to define the target population for ARM indication.</div></div><div><h3>Methods</h3><div>This prospective, observational, non-randomized study of patients with breast cancer included patients with an indication for axillary lymph node dissection (ALND) performed between June 2021 and June 2023. Participants were divided into two cohorts based on pattern of ICG migration: standard technique (all ARM nodes) and targeted technique (in contact with axillary vein). The feasibility of identifying and preserving ARM nodes during ALND was assessed. Multivariate logistic regression was used to analyze predictive factors (eg, tumor size, molecular surrogate subtype, multifocality, and neoadjuvant therapy) for metastatic ARM nodes.</div></div><div><h3>Results</h3><div>Of the 41 patients in whom we performed the ARM technique, ARM nodes were identified and preserved after ALND in 36 patients (87.8%). Of these, 17 (89.5%) underwent the standard technique and 19 (86.4%) underwent the targeted technique. ARM metastases were identified in 12 patients: 9 (47.1%) with the standard technique and 3 (15.7%) with the targeted technique (<em>P</em> = .026). The ARM technique was the only risk factor for ARM involvement (odds ratio, 15.9; 95% confidence interval, 1.1-218.6).</div></div><div><h3>Conclusions</h3><div>ICG facilitates the successful completion of ARM in almost 90% of patients undergoing ALND. In addition, by selecting the ARM nodes closest to the axillary vein, the number of cross metastases can be significantly reduced.</div></div>","PeriodicalId":10197,"journal":{"name":"Clinical breast cancer","volume":"25 3","pages":"Pages 268-276"},"PeriodicalIF":2.9,"publicationDate":"2024-12-07","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142926557","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Unveiling Inequities: Racial Disparities in Risk-Reducing Mastectomy for Breast Cancer Prevention","authors":"Samuel Knoedler ,&nbsp;Fortunay Diatta ,&nbsp;Felix J. Klimitz ,&nbsp;Olivier Noel ,&nbsp;Joanna Kempa ,&nbsp;Doha Obed ,&nbsp;Seung-Yong Song ,&nbsp;Horacio Mayer ,&nbsp;Bong-Sung Kim ,&nbsp;Martin Kauke-Navarro ,&nbsp;Bohdan Pomahac ,&nbsp;Paris D. Butler","doi":"10.1016/j.clbc.2024.12.004","DOIUrl":"10.1016/j.clbc.2024.12.004","url":null,"abstract":"<div><h3>Background</h3><div>Risk-reducing mastectomy (RRM) significantly lowers breast cancer risk as a preventive surgery. While racial disparities in breast cancer treatment are well-documented, research on racial differences in the utilization and outcomes of RRM is limited.</div></div><div><h3>Methods</h3><div>We retrospectively analyzed the American College of Surgeons National Surgical Quality Improvement Program (2008-2022) to identify women who underwent RRM. Patient demographics, comorbidities, surgical characteristics, and 30-day postoperative outcomes were compared between White and racial minority patients, including Black/African American women.</div></div><div><h3>Results</h3><div>Among 1,285 patients, 88% (n = 1,126) self-identified as White and 12.4% (n = 159) as racial minorities, including 5.8% (n = 74) Black. Minority patients were younger than White patients (50.7±11.4 years vs. 52.6±12.6 years; <em>P</em> = .66). Black patients had a significantly higher mean BMI than White patients (33.6±8.4 kg/m² vs. 30.6±8.0 kg/m²; <em>P</em> = .03), and higher prevalence of obesity (65%, n = 48 vs. 47%, n = 524; <em>P</em> = .03) and hypertension (51%, n = 38 vs. 30%, n = 342; <em>P</em> = .007). Racial minority patients were more likely to undergo outpatient surgery (81%, n = 129 vs. 57%, n = 645; <em>P</em> &lt; .001) and had shorter hospital stays than White patients (0.8±1.3 days vs. 1±2 days; <em>P</em> = .001). Black patients experienced higher rates of superficial incisional infections (9.5%, n = 7 vs. 2.9%, n = 33; <em>P</em> = .18) and overall complications (18%, n = 13 vs. 10%, n = 113; <em>P</em> = .48)</div></div><div><h3>Conclusion</h3><div>This multi-institutional study reveals racial disparities in RRM, with minority patients significantly more likely to present with comorbidities and experience higher complication rates. These findings underscore the need for targeted strategies to ensure equitable access to RRM and improve outcomes for minority patients, advancing health equity in breast cancer prevention.</div></div>","PeriodicalId":10197,"journal":{"name":"Clinical breast cancer","volume":"25 3","pages":"Pages e312-e320"},"PeriodicalIF":2.9,"publicationDate":"2024-12-06","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142913672","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Pyrotinib Plus Taxanes or Vinorelbine for the Treatment of Human Epidermal Growth Factor Receptor 2-Positive Metastatic Breast Cancer: Prospective Evaluation of Efficacy and Safety.","authors":"Weili Xiong, Jiukang Sun, Quan Gu, Ting Xu, Lili Zhang, Yuan Yuan","doi":"10.1016/j.clbc.2024.12.006","DOIUrl":"https://doi.org/10.1016/j.clbc.2024.12.006","url":null,"abstract":"<p><strong>Purpose: </strong>The clinical benefits of pyrotinib plus taxanes or vinorelbine have not been studied systemically. Consequently, we conducted a prospective evaluation to assess the efficacy and safety of pyrotinib plus taxanes or vinorelbine in patients with human epidermal growth factor 2 (HER2)-positive metastatic breast cancer (MBC).</p><p><strong>Methods: </strong>Patients with HER2-positive MBC were included to receive pyrotinib combined with taxanes or vinorelbine in Jiangsu Cancer Hospital. The primary endpoint was progression-free survival (PFS), and the secondary endpoints were objective response rate (ORR), disease control rate (DCR), clinical benefit rate (CBR), and adverse effects (AEs).</p><p><strong>Results: </strong>Between December 22, 2020 and January 11, 2023, a total of 101 patients were assigned to pyrotinib plus taxanes (n = 83) and pyrotinib plus vinorelbine (n = 18) groups. As of May 24, 2023, the median PFS for all patients was 11.5 months (95% confidence interval [CI], 8.8-15.7). The median PFS was significantly longer in pyrotinib plus taxanes group than in pyrotinib plus vinorelbine group (median PFS, 12.2 months [95% CI, 9.2-18.6] vs. 8.4 months [95% CI, 5.5-13.7]; P = .005). All the treatment-related side effects were tolerated. The most frequent grade 3 or 4 side effects included diarrhea (22.8%), leukopenia (19.5%), and neutropenia (18.2%).</p><p><strong>Conclusion: </strong>Pyrotinib plus taxanes could be an alternative or even the preferred treatment strategy for patients with HER2-positive MBC after trastuzumab and small-molecule tyrosine kinase inhibitors (TKIs). We also suggest that pyrotinib combined with vinorelbine has a therapeutic potential.</p><p><strong>Registration: </strong>This trial was registered in Chinese Clinical Trial Registry. URL: https://www.chictr.org.cn/showproj.html?proj=65697 (ChiCTR2000041217).</p>","PeriodicalId":10197,"journal":{"name":"Clinical breast cancer","volume":" ","pages":""},"PeriodicalIF":2.9,"publicationDate":"2024-12-05","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142892553","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Muscle Quality May Improve With Regular Exercise, Improving the Prognosis for Breast Cancer Patients","authors":"Kadri Altundag","doi":"10.1016/j.clbc.2024.12.005","DOIUrl":"10.1016/j.clbc.2024.12.005","url":null,"abstract":"","PeriodicalId":10197,"journal":{"name":"Clinical breast cancer","volume":"25 3","pages":"Page e321"},"PeriodicalIF":2.9,"publicationDate":"2024-12-05","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142892549","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"A Comparative Analysis of the Value of HER2 Immunohistochemistry Scoring in Primary and Metastatic Breast Cancer, in the Era of HER2 \"Low\" Breast Cancers.","authors":"Swati Bhardwaj, Shabnam Jaffer","doi":"10.1016/j.clbc.2024.11.017","DOIUrl":"https://doi.org/10.1016/j.clbc.2024.11.017","url":null,"abstract":"<p><strong>Background: </strong>In the DESTINY-B04 trial, patients with pretreated HER2 low metastatic breast cancer (defined as immunohistochemistry score of 1+ or 2+ and negative in situ hybridization) had significant survival improvement with Trastuzumab therapy.</p><p><strong>Methods: </strong>The goal of our study was to compare the HER2 immunohistochemistry scores of paired primary and metastatic breast cancer, with emphasis on HER2 low criteria and its implications for detailed immunohistochemistry interpretation. Using the pathology database from 2011, we identified 272 cases of primary breast cancers with paired metastases. We reviewed and performed immunohistochemistry concordance between the primary and metastases and calculated the HER2 low incidence.</p><p><strong>Results: </strong>Compared to the primary, HER2 immunohistochemistry score in the metastases remained the same in 156/272 cases (57%) and by immunohistochemistry was: 0 (67/114 = 59%), 1+ (22/52 = 42%), 2+ (34/67 = 51%), 3+ (33/39 = 85%) and HER2 low (85/119 = 71%). The HER2 score changed from 0 to HER2 low in 46 cases (17%) and vice versa in 30 (11%).</p><p><strong>Conclusions: </strong>The concordance rate of HER2 immunohistochemistry scores was 57%, highest in 3+ cases, followed by HER2 low and then HER2 negative. The incidence of HER2 low was higher in the metastases by 6% compared to the primary. HER2 should be tested in all metastases and compared with the primary, due to differences in scores as seen in 28% of our cases, which may have clinical implications in the new HER2 low era.</p>","PeriodicalId":10197,"journal":{"name":"Clinical breast cancer","volume":" ","pages":""},"PeriodicalIF":2.9,"publicationDate":"2024-12-04","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142892542","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Universal Genetic Counseling and Testing for Black Women: A Risk-Stratified Approach to Addressing Breast Cancer Disparities","authors":"Versha A. Pleasant ,&nbsp;Sofia D. Merajver","doi":"10.1016/j.clbc.2024.11.024","DOIUrl":"10.1016/j.clbc.2024.11.024","url":null,"abstract":"<div><div>Black women experience disproportionate breast cancer-related mortality, with similar overall incidence to White women. Approaches to address these racial health disparities should be multifaceted. Universal genetic counseling and testing for Black women could represent one dimension of a comprehensive approach in guiding early identification of those more likely to experience higher breast cancer-related mortality. The increased risk of triple-negative breast cancer and greater likelihood of early-onset breast cancer among Black women are 2 major justifications, given that these elements are already preexisting testing criteria per the National Comprehensive Cancer Network. Increasing assessment of breast cancer-related risk in the Black community through universal genetic counseling and testing should be considered to focus enhanced screening and preventive measures in a tailored risk-appropriate context.</div></div>","PeriodicalId":10197,"journal":{"name":"Clinical breast cancer","volume":"25 3","pages":"Pages 193-197"},"PeriodicalIF":2.9,"publicationDate":"2024-12-04","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142892559","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Investigation of HOTAIR rs12826786, rs920778 and rs4759314 Variants With Breast Cancer Susceptibility and Clinicopathological Characteristics in a Mexican Population.","authors":"Mónica Alejandra Rosales-Reynoso, Clara Ibet Juárez-Vázquez, Isabel Nohemí García-Sánchez, Alejandra Palacios-Ramírez, Miriam Yadira Godínez-Rodríguez, César de Jesús Tovar-Jácome, Claudia Azucena Tapia-Leyva, Gerardo Emmanuel Robledo-López, José Elías García-Ortiz, Efraín Salas-González, Aldo Antonio Alcaraz-Wong, Martha Patricia Gallegos-Arreola","doi":"10.1016/j.clbc.2024.11.021","DOIUrl":"https://doi.org/10.1016/j.clbc.2024.11.021","url":null,"abstract":"<p><strong>Background: </strong>Breast cancer (BC) is a multifactorial disease of unknown etiology whose major risk factors are genetic alterations of cell proliferation and migration pathways. HOX transcript antisense RNA gene (HOTAIR) is a long noncoding RNA (lncRNA) related to cell proliferation, progression, invasion, metastasis, and poor survival of multiple cancers, including BC. Controversial results have emerged on the association between breast cancer risk in multiple ethnicities. This study explores the association of rs12826786, rs920778, and rs4759314 variants in the HOTAIR gene in BC patients.</p><p><strong>Methods: </strong>DNA of peripheral blood samples was obtained from 588 women (289 patients and 299 control females). Genotypes were identified using polymerase chain reaction-restriction fragment length polymorphism (PCR-RFLP) methodology. The association was calculated using the odds ratio (OR) test. p-values were adjusted by the Bonferroni test (0.016).</p><p><strong>Results: </strong>The rs12826786 (C > T), rs920778 (T > C), and rs4759314 (A > G) variants were associated with BC and with TNM stage, histologic type, and histologic molecular subtype (P = .001). Likewise, the haplotype C-T-G in the HOTAIR gene (rs12826786-rs920778-rs4759314) was significantly related to BC (OR = 5.44, 95% CI, 2.22-13.32, P = .001).</p><p><strong>Conclusion: </strong>The results suggest that rs12826786, rs920778, and rs4759314 variants in HOTAIR significantly influence breast cancer risk.</p>","PeriodicalId":10197,"journal":{"name":"Clinical breast cancer","volume":" ","pages":""},"PeriodicalIF":2.9,"publicationDate":"2024-12-03","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142892546","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Breast Cancers With Intermediate Estrogen Receptor Expression: Characteristics, Prognosis and Treatment","authors":"Ioannis A. Voutsadakis","doi":"10.1016/j.clbc.2024.11.020","DOIUrl":"10.1016/j.clbc.2024.11.020","url":null,"abstract":"<div><div>In the era of personalized oncology biomarkers that identify subgroups of specific cancers and help predict response to specific therapies are critical tools for prognosis determination and therapeutic decisions. The Estrogen Receptor (ER) had been one of the first biomarkers used in breast cancer and has helped advance the field of breast oncology by contributing to the success of hormonal therapies for the ER positive subgroup of the disease. Expression of the receptor in 1% or more of tumor cells in immunohistochemical sections define currently the ER positive subgroup of breast cancers, which may be treated with regimens that include hormonal inhibitors. The highest sensitivity and benefit of hormonal therapies is observed in cancers with robust ER expression (in 90% to 100% of tumor cells). However, it has become clear that the subgroup of breast cancers with low ER expression (in 1% to 10% of tumor cells) behaves similarly to ER negative breast cancers and has an inferior response to hormonal therapies. The behavior of the rest of ER positive breast cancers with an intermediate ER expression between these 2 extremes (ER expression between 10% and 90%) is less well described and their response to estrogen targeting therapies is less clear. Breast cancers with intermediate ER expression represent a small subgroup of ER positive breast cancers and the wide range of expressions suggests heterogeneity. This review will discuss this subgroup of ER positive breast cancers and examine their genomic landscape and therapeutic repercussions.</div></div>","PeriodicalId":10197,"journal":{"name":"Clinical breast cancer","volume":"25 3","pages":"Pages 214-222"},"PeriodicalIF":2.9,"publicationDate":"2024-12-03","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142876329","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}